Optimal Usage of Sacubitril/Valsartan for the Treatment of Heart Failure: The Importance of Optimizing Heart Failure Care in Canada
| Autor: | Robert S. McKelvie, Sean A. Virani, Ashlay A. Huitema, Shelley Zieroth, Alexia Daoust, Michel White, Carlos Rojas-Fernandez, Kim Anderson, Stephanie Poon |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.medical_specialty education.field_of_study Ejection fraction Standard of care business.industry Population medicine.disease Sacubitril Valsartan lcsh:RC666-701 Heart failure Emergency medicine medicine Original Article In patient Cardiology and Cardiovascular Medicine education business Sacubitril Valsartan medicine.drug |
| Zdroj: | CJC Open CJC Open, Vol 2, Iss 5, Pp 321-327 (2020) |
| ISSN: | 2589-790X |
| Popis: | Background: Heart failure (HF) with reduced ejection fraction represents approximately 50% of the 600,000 Canadians currently living with HF and over 90,000 new cases diagnosed each year. The angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, demonstrated superior efficacy in reducing cardiovascular death and HF hospitalization over standard of care therapy. Methods: The potential magnitude of benefit in Canada with respect to preventing or postponing deaths and reducing hospitalizations resulting from its optimal implementation in patients with HF with an ejection fraction |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|